Related Experiment Videos
Familial Mediterranean fever. Recent advances in pathogenesis and management
Abstract:
The success of colchicine therapy in the management of familial Mediterranean fever has provided new direction to investigations into the pathogenesis of this disease. Examination of HLA antigen frequencies in 53 patients with familial Mediterranean fever and appropriate controls, as well as various immunologic studies have yielded no significant differences. However, B lymphocyte typing and assays for immune complexes, lymphokines and prostaglandins may be of potential interest. Preliminary studies indicate that leukocytes of patients with familial Mediterranean fever release increased amounts of lysozyme (P<0.01), when subjected to high temperatures, and of both lysozyme and myeloperoxidase at low osmotic concentrations. The known and potential effects of colchicine on leukocyte and cellular metabolism, and the current status of colchicine prophylaxis are reviewed. In patients receiving an optimum colchicine dose of 1.5 to 1.8 mg per day, side effects have been minimal and the frequency of attacks has been decreased significantly.
Insights
Colchicine therapy effectively manages familial Mediterranean fever by reducing attack frequency with minimal side effects. Leukocyte studies reveal potential insights into the disease
Area of Science:
- Immunology
- Genetics
- Rheumatology
Background:
- Familial Mediterranean fever (FMF) is a genetic autoinflammatory disorder.
- Colchicine is a successful treatment for FMF, prompting further research into its pathogenesis.
- Previous studies found no significant differences in HLA antigen frequencies or general immunologic markers between FMF patients and controls.
Purpose of the Study:
- To investigate the pathogenesis of familial Mediterranean fever.
- To explore potential immunologic markers and cellular responses in FMF patients.
- To review the effects and efficacy of colchicine therapy in FMF management.
Main Methods:
- Examination of HLA antigen frequencies in 53 FMF patients and controls.
- Various immunologic studies, including B lymphocyte typing and immune complex assays.
- Analysis of leukocyte release of lysozyme and myeloperoxidase under thermal and osmotic stress.
Main Results:
- No significant differences were observed in HLA antigen frequencies or general immunologic studies.
- Preliminary findings indicate increased lysozyme release from FMF leukocytes at high temperatures (P<0.01).
- Leukocytes from FMF patients showed increased release of lysozyme and myeloperoxidase at low osmotic concentrations.
Conclusions:
- While traditional immunologic markers show no differences, specific leukocyte responses to stress may be relevant to FMF pathogenesis.
- Colchicine therapy is highly effective in reducing FMF attack frequency.
- Optimal colchicine dosage (1.5-1.8 mg/day) results in minimal side effects and significant clinical improvement.